Show simple item record

dc.contributor.authorMcNamara, Mairead G
dc.contributor.authorScoazec, J. Y.
dc.contributor.authorWalter, T.
dc.date.accessioned2020-11-16T07:49:13Z
dc.date.available2020-11-16T07:49:13Z
dc.date.issued2020en
dc.identifier.citationMcNamara MG, Scoazec JY, Walter T. Extrapulmonary poorly differentiated NECs, including molecular and immune aspects. Endocr Relat Cancer. 2020;27(7):R219-R38.en
dc.identifier.pmid32357308en
dc.identifier.doi10.1530/erc-19-0483en
dc.identifier.urihttp://hdl.handle.net/10541/623410
dc.description.abstractPatients with extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PD-NECs) have a poor prognosis. Surgery is offered for those with localised disease, but the majority of patients present with advanced disease. Treatment strategies adopted are analogous to that of high grade NECs of the lung, with platinum/etoposide-based regimens advocated in the first-line setting for advanced disease. There is no standard second-line therapy. Research into their molecular and immune pathways may pave the way for novel drug discovery. The molecular drivers of NEC are best identified in small cell lung carcinoma, which present with near universal genomic alterations in TP53 and RB1. The genetics of EP-PD-NEC remain poorly understood; TP53, KRAS, PIK3CA/PTEN and BRAF mutations have been identified, with alterations in the BRCA pathway reported additionally in small cell NEC of the cervix and absence of argininosuccinate synthetase 1 expression in NEC of the urinary bladder. The use of cell lines and patient-derived xenografts (PDX) to predict response to treatment in NEC and the emergence of alternative biomarkers, such as circulating tumour cells and cell-free DNA, will also be explored. Despite limited published data on the immune microenvironment of EP-NEC, there are a number of clinical trials investigating the use of immune-targeted agents in this disease category, with conflicting emerging data from studies thus far. This review will summarise the treatment and available molecular and immune data in this under researched diagnosis and may stimulate the direction of future exploratory studies.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1530/erc-19-0483en
dc.titleExtrapulmonary poorly differentiated NECs, including molecular and immune aspectsen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalEndocrine-Related Canceren
dc.description.noteen]
refterms.dateFOA2020-11-17T10:16:18Z


Files in this item

Thumbnail
Name:
32357308.pdf
Size:
898.9Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record